Tumor necrosis factor alpha (TNFα) is a key cytokine involved in immune and inflammatory responses. TNFα is produced primarily by macrophages, but it can be generated by other leukocytes as well as endothelial cells, cardiomyocytes and other cell types. TNFα binding to its receptors, TNF receptor type 1 (TNFR1) and TNFR2, induces a myriad of cellular responses that are cell-context dependent. Typically, TNFα binding to TNFR1 and/or TNFR2 induces pro-inflammatory responses, such as immune cell activation, promotion of effector functions and cytokine production, as well as the acute phase response. TNFα exists in both a trimeric membrane-bound form (mTNFα) and as a soluble protein. Binding of TNFα-targeted antibodies to mTNFα-expressing cells can induce effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) to destroy the mTNFα-expressing inflammatory cells. However, such studies are hampered by the lack of model cell lines naturally expressing mTNFα.
mTNFα Target Cells are a genetically engineered cell line stably expressing TNFα on the cell surface. They are designed to be used as target cells in assays that measure the effector functions, such as ADCC and CDC, of anti-TNFα blockers. In addition, they can be used to measure antibody binding affinity to mTNFα.